Philip He

7PUBLICATIONS
58CO-AUTHORS
Epidemiological modellingCancer therapy (excl. chemotherapy and radiation therapy)ChemotherapyPredictive and prognostic markersGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Aug 06, 2026
Applying the estimand framework to safety: aligning estimators with treatment effects in the presence of intercurrent events.

|Jul 01, 2026
Implementing Project Optimus in Oncology Dosage Optimization: Where are We Now?

|May 11, 2025
Correlation between tumor growth rate and survival in patients with metastatic breast cancer treated with trastuzumab deruxtecan.

Philip He, Dhiraj Gambhire, Haiming Zhou

|Dec 28, 2024
A Bayesian Hybrid Design With Borrowing From Historical Study.

Zhaohua Lu, John Toso, Girma Ayele

|Feb 22, 2023
Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.

Sophie Wildsmith, Weimin Li, Song Wu

|Dec 08, 2022
Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma.

Xuyang Song, Robin Kate Kelley, Anis A Khan

Pageof 2

Frequent Collaborators

2 joint publications

Robin Kate Kelley

2 joint publications

Ghassan K Abou-Alfa

1 joint publications

Masafumi Ikeda

1 joint publications

Takuji Okusaka